// App-Quantinova.ai

776 : Androgen receptor (AR) and non-AR aberrations associated with outcomes in metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) plus androgen deprivation therapy (ADT) in TITAN

Researchers

Presenter

  • Kim N. Chi

Principal Investigators

  • Shibu Thomas

  • Michael Gormley

  • Dong Shen

  • Neeraj Agarwal

  • Felix Feng

  • Gerhardt Attard

  • Alex Wyatt

  • Deborah S. Ricci

  • Angela Lopez-Gitlitz

  • Julie S. Larsen

  • Branko Miladinovic

  • Simon Chowdhury

Medical Centers

  • Vancouver Prostate Ctr., Vancouver, British Columbia, Canada

  • Janssen Research and Development, LLC, Spring House, PA

  • Hunstman Cancer Institute of Utah, Salt Lake City, UT

  • Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA

  • Bart's Cancer Institute, London, United Kingdom

  • The University of British Columbia, Vancouver, BC, Canada

  • Janssen Research & Development, Los Angeles, CA

  • Janssen Research & Development, San Diego, CA

  • Guys, Kings and St. Thomas Hospitals, and Sarah Cannon Research Institute, London, United Kingdom

Locations

  • Canada

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • Androgen receptor

  • Plasma cell-free DNA

Drug/Treatment

  • Androgen Tear

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved